TVGNTevogen Bio Holdings Inc.

$10.60
$0.00
(0.00%)
Pre-Market
Updated: 04:04 AM EDT·Prev Close $10.60
EarningsAug 13
Mkt Cap$45.02M
Vol20.00
News
all
press releases
Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions
The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.
Stocktwits
News Placeholder
More News
News Placeholder
Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month Low - Here's What Happened
Tevogen Bio (NASDAQ:TVGN) Reaches New 12-Month Low - Should You Sell...
MarketBeat
News Placeholder
Tevogen Shares Take Further Beating On Gauging Deal With Apozel Pharmaceuticals
If the deal goes through, it could provide Tevogen with an established generics platform, the company said.
Stocktwits
News Placeholder
Tevogen Bio (TVGN) to Release Earnings on Wednesday
Tevogen Bio (NASDAQ:TVGN) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...
MarketBeat
News Placeholder
Tevogen Bio (NASDAQ:TVGN) Trading 7.9% Higher - Should You Buy?
Tevogen Bio (NASDAQ:TVGN) Stock Price Up 7.9% - Should You Buy...
MarketBeat
News Placeholder
Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why
Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's What Happened...
MarketBeat
News Placeholder
Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Time to Sell?
Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Here's What Happened...
MarketBeat
News Placeholder
Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital
D. Boral Capital decreased their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...
MarketBeat
News Placeholder
Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results
Tevogen Bio (NASDAQ:TVGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter...
MarketBeat
News Placeholder
Buy When There’s Blood in the Streets: Why the DeepSeek Rout May Be Good News for Microsoft Stock
Microsoft’s stock presents a buying opportunity due to its strong financials, strategic partnerships, and potential to benefit from cheaper AI models in the long run.
barchart.com
<
1
2
...
>

Advertisement|Remove ads.